|
 |
SirolimusThis page contains recent news articles, when available, and an overview of Sirolimus but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Sirolimus (when available) Sirolimus, a macrocyclic lactone produced by Streptomyces hygroscopicus, is an immunosuppressive agent indicated for the prophylaxis of organ rejection in patients receiving renal transplants. It is recommended that Sirolimus be used in a regimen with cyclosporine and corticosteroids. For the treatmnet of post operative pain Mechanism Of Action: Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, Sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The Sirolimus:FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle. News Articles on Sirolimus TCTMD's Top 10 Most Popular Stories for 2009 - Jan 4, 2010 In the latest study, a system combining a paclitaxel-eluting balloon with a bare-metal stent did not reach noninferiority against a sirolimus-eluting stent ... TCTMD New data for second-generation DES should reassure doctors on safety, efficacy ... - Dec 29, 2009 Three-year results from the ENDEAVOR III trial, comparing the Endeavor DES with the Cypher sirolimus-eluting stent, suggesting that the newer stent is ... TheHeart.Org Study Links Bone Marrow Transplant to Effective Treatment of Sickle Cells in ... - Dec 10, 2009 The study, which involved 10 patients ranging from the 16-45 age group, placed then on the drug alemtuzumab, low radiation doses and sirolimus, ... TopNews New Zealand Allogeneic hematopoietic stem-cell transplant protocol successful in adult ... - Dec 10, 2009 A protocol that combines allogeneic hematopoietic stem cell transplantation with total-body irradiation and treatment with alemtuzumab and sirolimus allowed ... HemOncToday Getting a Handle on Posttransplant Recurrence of HCC - Dec 17, 2009 Two other promising agents that are unproven include the oral agent sorafenib (Nexavar), and the immunosuppressant sirolimus (Rapamune). ... Cancer Network Trials DECLARE Benefits of Cilostazol Persist Long Term - Dec 14, 2009 In the DECLARE-DIABETES and DECLARE-LONG trials, patients with diabetes and long lesions, respectively, were first randomized to sirolimus-eluting or ... TCTMD Repeat late instent-stenosis after an interval of four years in the same ... - Dec 31, 2009 Again a DES implanted. Therefore the processes involved in the late instent-stenosis were not influenced by the antiproliferative agent sirolimus. 7thSpace Interactive (press release) RPG plans to focus on nephrology business - Dec 10, 2009 He gives the example of immuno-suppressant Sirolimus, used to prevent transplanted organ rejection by the body, which the company introduced in August this ... mydigitalfc.com Reversing sickle cell disease in adults - Dec 14, 2009 To achieve this goal, the investigators used a low dose of radiation to the whole body and two drugs, alemtuzumab and sirolimus, to suppress the immune ... WANE One in five heart-transplant patients get skin cancer within five years - Dec 29, 2009 Tacrolimus and sirolimus were nonsignificantly correlated with a decreased risk of basal-cell and squamous-cell carcinomas, respectively. ... TheHeart.Org מהו ×”×¡×˜× ×˜ המצופה המועדף ל×?חר ×?וט×? שריר הלב?! - Dec 27, 2009 ...×”×¡×˜× ×˜ מהדור ×”×©× ×™ הו×? ×–×” המצופה ZOTAROLIMUS בעוד ×©×”×¡×˜× ×˜×™×? מהדור הר×?שון ×”×? ×?ילו המצופי×? ב - PALITAXEL ×?ו ב - SIROLIMUS. הירחון ×”×?מריק×?×™ לקרדיולוגיה מבי×? מחקר ... מרכז הרופאים המומחים Makin Aman dengan Cincin - Dec 27, 2009 NEVOâ„¢ Sirolimus eluting Coronary Stent namanya. Tetap memakai sirolimus. Bedanya, bahan stent itu terbuat dari polyglycolic acid dan polylactic acid, ... MBM Tempo (Berlangganan) 골수ì?´ì‹?, 겸ìƒ? ì ?혈구병 치료 - Dec 10, 2009 ...사ì?˜ 백혈병 ì¹˜ë£Œì œë¡œ T세í?¬ ë©´ì—시스템 ì–µì œì—? 사용ë?˜ëŠ” 'ì•Œë ˜íˆ¬ì£¼ë§µ(Alemtuzumab)'ê³¼ '시롤리무스(sirolimus)'를 복용케 í•œ ê²°ê³¼ 예후가 매우 ì¢‹ì•˜ë‹¤ê³ ë°?혔다. ... 헬스코리아뉴스 Sichelzellanämie: Stammzellen für Erwachsene - Dec 10, 2009 Den jetzt erreichten Erfolg führt der Arzt auf die beiden neuen Medikamente zurück, die das Team eingesetzt hatte: Alemtuzumab und Sirolimus. ... NetDoktor.de "Ardi" führt Spitze der Top Ten an - Dec 18, 2009 Der Wirkstoff, der auch unter dem Namen Sirolimus bekannt ist, schiebt den Alterungsprozess von Säugetieren auf: Mäuse, an denen er in einem amerikanischen ... Wiener Zeitung Pacientes renales sin medicinas en el IHSS - Dec 14, 2009 En sus cartas manifiestan que desde agosto se les ha disminuido medicamentos como el sirolimus. Los denunciantes además han expresado que se han suspendido ... Diario La Prensa Mini-transplantes podem reverter a doença falciforme - Dec 10, 2009 Unidos usaram uma dose bem menor de radiação para "criar espaço" para as novas células, e usaram a droga sirolimus para prevenir essas complicações. ... Gazeta de Alagoas Pani Sophie ma 227 lat i... gdzieÅ› siÄ™ zawieruszyÅ‚a - Dec 25, 2009 ...które już, już, prawie majÄ… piguÅ‚ki dÅ‚ugowiecznoÅ›ci: a to rapamycynÄ™, a to wykryty w glebie Wysp Wielkanocnych sirolimus, to znów komórki macierzyste. ... Gazeta Lubuska 2009-12-21TvÃ¥ medicinska upptäckter tas med när tidskriften Science listar ... - Dec 21, 2009 Det handlar dels om det immundämpande läkemedlet rapamycin, eller sirolimus, som normalt används mot organavstötning vid njurtransplantationer. ... Dagens Medicin Técnica intervencionista alternativa para lesiones ostiales de la arteria ... - Dec 14, 2009 Los stents farmacoactivos implantados fueron sirolimus en 24 (34%) pacientes, paclitaxel en 11 (15%), everolimus en 25 (35%) y zotarolimus en 11 (15%). ... theheart.org „Mini“-Stammzelltransplantation bessert Sichelzellanämie - Dec 10, 2009 Dies bedeutet, dass die Patienten weiterhin das Immunsuppressivum Sirolimus einnehmen müssen und den Nebenwirkungen dieses Wirkstoffs ausgesetzt sind: Bei ... Deutsches Ärzteblatt Mesothelioma Treatment Improved with Addition of Sirolimus - Nov 12, 2009 Researchers at the Brigham and Women's Hospital in Boston, Massachusetts have found that adding sirolimus to chemotherapy with cisplatin was more effective ... Asbestos.com Converting to Sirolimus From Calcineurin Inhibitors Reduces Risk of Skin ... - Oct 31, 2009 ...[Presentation title: Kidney Transplant Recipients at High Risk for Non-Melanoma Skin Cancer (NMSC) May Benefit From Conversion to Sirolimus Versus ... DG News Switching Immunosuppressants Reduces Cancer Risk In Kidney - Nov 1, 2009 The other group was switched to treatment with sirolimus -- one of a newer class of immunosuppressants called mTOR inhibitors. ... Science Daily (press release) MacuSight(R) Receives Fast Track Designation From FDA for Perceiva(TM) in ... - Oct 21, 2009 About Perceiva MacuSight's lead product candidate, Perceiva, is a proprietary ocular formulation of sirolimus. As an mTOR inhibitor, sirolimus possesses a ... Reuters Rapamuneâ„¢ May Improve Responses to Gleevec® in Patients with Chordoma - Nov 4, 2009 Researchers from Italy have reported that the addition of Rapamune® (sirolimus, rapamycin) to Gleevec® (imatinib) may improve disease control in patients ... Cancer Consultants CCI Journal Publishes Sahajanand Medical Technologies PAINT trial 1 year results - Nov 3, 2009 The Sirolimus drug-eluting Stents, Paclitaxel drug eluting Stents and Bare metal Stents were successfully implanted in a (2:2:1) randomization. ... International Business Times (press release) DES fractures occur more often than thought - Nov 12, 2009 They found that longer stent length, Cypher sirolimus-eluting stent (Cordis/Johnson & Johnson) usage, and longer duration of stent implant were independent ... TheHeart.Org SurModics, Inc.Q4 2009 Earnings Call Transcript - Nov 4, 2009 Specifically, Johnson & Johnson reported that sales for the quarter of the Cypher Sirolimus-eluting Coronary Stent were approximately $211 million, ... Seeking Alpha (blog) FDA grants MacuSight fast track designation for DME drug - Oct 22, 2009 Perceiva is an ocular formulation of sirolimus, an mTOR inhibitor designed for minimally invasive, sustained and local delivery. ... OSN SuperSite Non-Cardiac Surgery and Antiplatelet Therapy Following Coronary Artery Stenting - Oct 30, 2009 ...aspirin and clopidogrel therapy after bare-metal stenting (BMS), 3 months after sirolimus-eluting stents, and 6 months after paclitaxel-eluting stents. ... Cardiosource FDA Safety Changes: Ultram, Ultracet, Sustiva, Kayexalate - Oct 28, 2009 ...exposure to immunosuppressants metabolized by the hepatic cytochrome P450 isoenzyme 3A4 (CYP 3A4), such as cyclosporine, sirolimus, and tacrolimus. ... Medscape Les stents pharmacoactifs - Oct 28, 2009 Ces agents antiprolifératifs sont issus de la pharmacopée anticancéreuse : sirolimus ou rapamycine (agent cytostatique, développé pour son action ... John Libbey Eurotext Risk factors for and management of sirolimus-associated pneumonitis... - Dec 31, 2007 Weiner SM et al. (2007) Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome—a single-centre experience and review of ... Nature.com Sirolimus stent best for diabetic heart disease - Jan 5, 2008 NEW YORK (Reuters Health) - As a treatment for heart disease in diabetics, stents that release sirolimus, an immune-suppressing drug, are more effective ... Reuters India … following conversion from azathioprine to sirolimus in renal... - Aug 16, 2006 Correspondence: JM van den Akker, Department of Nephrology 464, Radboud University Nijmegen Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands. ... Nature.com Johnson & Johnson's heart stent fails trial, derailing US plans - May 8, 2007 Officers of Johnson & Johnson said it would focus on using sirolimus, the more potent drug the Cypher delivers, in the CoStar's unique stent design. ... New York Times Sirolimus as primary immunosuppression is effective in attenuating … - Feb 29, 2008 Raichlin E et al. (2007) Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac ... Nature.com CYP3A5*3 influences sirolimus oral clearance in de novo and stable … - May 9, 2005 1 Service de Néphrologie and Service de Pharmacologie-Toxicologie, Centre Hospitalier Universitaire, LimogesService de Pharmacologie and Service de ... Nature.com Worse renal transplant outcomes with sirolimus–mycophenolate than... - Apr 10, 2007 Srinivas TR et al. (2007) Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. ... Nature.com Anti-Rejection Drug May Boost Diabetes in Kidney Transplant Patients - May 22, 2008 Compared to other anti-rejection drugs, sirolimus was associated with a 36 ... "We demonstrated a robust association between sirolimus and diabetes after ... ABC News A Drug Used After Organ Transplants Could Fight Some Cancers - Mar 31, 2005 In a study appearing in the March 31 issue of The New England Journal of Medicine, doctors found that the immunosuppressive drug sirolimus, or rapamycin, ... New York Times How do sirolimus-eluting and paclitaxel-eluting stents compare in... - May 25, 2006 Stettler C et al. (2006) Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials. ... Nature.com Changing Heart Transplant Drugs Could Boost Kidney Function - Apr 26, 2007 The second study of 29 patients found that a gradual switch to sirolimus reduced development of changes related to transplant coronary artery disease. ... Washington Post How cost-effective are sirolimus-eluting stents when compared with... - Jun 13, 2005 ...van Hout BA et al. (2005) One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo ... Nature.com The place of sirolimus in kidney transplantation: Can we reduce … - Jul 26, 2006 Correspondence: BD Kahan, Division of Immunology and Organ Transplantation, The University of Texas Health Science Center at Houston, 6431 Fannin Street, ... Nature.com Tirofiban and Sirolimus Stents in Primary PCI - Mar 30, 2008 March 30, 2008 (Chicago, IL) – High-dose tirofiban was "noninferior" to abciximab in terms of resolution of ST-segment elevation at 90 minutes in STEMI ... Medscape US FDA says Roche cancels heart transplant study - Feb 22, 2007 ..."The safety and efficacy of CellCept in combination with sirolimus following withdrawal of initial calcineurin inhibitor therapy has not been established," ... Reuters Do the beneficial effects of sirolimus-eluting stents extend beyond 1... - Jun 10, 2005 Fajadet J et al. (2005) Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents. Three-year results of the RAVEL trial. ... Nature.com Sirolimus-releasing stents more effective than VBT for treating... - Mar 12, 2006 David R. Holmes, Jr., MD, of Mayo Clinic, Rochester, Minn., and colleagues with the SISR trial compared the use of vascular brachytherapy (VBT ... eurekalert.org Easter island drug fights tumours - Jan 10, 2008 The UK study tested the effects of sirolimus on kidney tumours in patients with tuberous sclerosis and a related condition, LAM, a lung and kidney disease ... Telegraph.co.uk Economic evaluation of sirolimus-eluting stents.(Research/Recherche) - Feb 1, 2005 Background: Sirolimus-eluting stents have recently been shown to reduce the risk of restenosis among patients who undergo percutaneous coronary intervention ... Free with registration - CMAJ: Canadian Medical Association... - AccessMyLibrary.com Are sirolimus-eluting stents superior to paclitaxel-eluting stents in... - Nov 12, 2007 Togni M et al. (2007) Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the ... Nature.com Sirolimus-Eluting Stents vs Vascular Brachytherapy for In-Stent … - Mar 15, 2006 David R. Holmes Jr, MD; Paul Teirstein, MD; Lowell Satler, MD; Michael Sketch, MD; James O'Malley, PhD; Jeffery J. Popma, MD; Richard E. Kuntz, MD, MSc; ... Journal of American Medical Association - Journal of American Medical Association... Transplant drug sirolimus shrinks tumours, improves lung function - Jan 10, 2008 New technique could eliminate inherited mitochondrial disease — [26 Aug 2009] — Researchers have developed an experimental technique with the potential to ... Science Centric Stents Go Under the Microscope - Aug 16, 2005 ...that enable the drugs to be released from the stents, or the drugs themselves. Cypher uses a drug called sirolimus, while Taxus uses the drug paclitaxel. TheStreet.com - TheStreet.com (subscription) Sirolimus-Based Therapy Results in 90% Graft Survival in High-Risk … - Nov 20, 2006 By Ed Susman. SAN DIEGO, CA -- November 20, 2006 -- Sirolimus-based anti-rejection therapy resulted in 90% graft survival after 1 year in high-risk patients ... DG News … Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent... - Sep 2, 2008 Study Question: What is the safety and efficacy of a biolimus-eluting stent (with biodegradable polymer) compared with a sirolimus-eluting stent (with ... Cardiosource Better Outcomes with the Cypher(r) Sirolimus-Eluting Coronary Stent - Oct 17, 2005 Newswise — Results from the SISR trial, a multi-center, randomized study of the CYPHER® Sirolimus-eluting Coronary Stent versus radiation from within a ... newswise.com CYPHER(R) Sirolimus-eluting Coronary Stent Had Similar Results to … - Mar 26, 2007 NEW ORLEANS, March 26 /PRNewswire-FirstCall/ -- Three-year follow-up data presented today at the American College of Cardiology's 56th Annual Scientific ... Free with registration - PR Newswire - AccessMyLibrary.com Sirolimus- vs Paclitaxel-Eluting Stents in De Novo Coronary Artery … - Feb 22, 2006 Context Compared with bare metal stents, sirolimus-eluting and paclitaxel-eluting stents have been shown to markedly improve angiographic and clinical ... Journal of American Medical Association - Journal of American Medical Association... CYPHER SIROLIMUS-ELUTING CORONARY STENT OUTPERFORMS … - Oct 21, 2005 The most comprehensive and detailed analysis conducted to date of drug-eluting stent comparative trials shows a marked difference in the rate of target ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com What Type Of Drug-Coated Stent Is Best? Should I Request A Specific … - Feb 8, 2008 One is called paclitaxel and the other is called sirolimus. These are very fancy terms, but they essentially do the same things, and that is: they inhibit ... ABC News … Excellent Outcomes for CYPHER® Sirolimus-Eluting Coronary Stent in... - Oct 24, 2007 Washington, DC .– Implantation of the CYPHER® Sirolimus-eluting Coronary Stent to treat completely blocked coronary arteries led to substantial reductions ... webwire.com Sirolimus (Systemic). - Feb 1, 2006 Sirolimus (sir-OH-li-mus) belongs to a group of medicines known as immunosuppressive agents. It is used to lower the body's natural immunity in patients who ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Sirolimus (Systemic).(Drug overview) - Aug 1, 2006 Sirolimus (sir-OH-li-mus) belongs to a group of medicines known as immunosuppressive agents. It is used to lower the body's natural immunity in patients who ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com CYPHER® Sirolimus-Eluting Coronary Stent Demonstrates Sustained … - Apr 2, 2007 Clinical investigators at the American College of Cardiology's 56th Annual Scientific Session (ACC.07) reported today that the clinical benefit of the ... Medical News Today - Medical News Today (press release) … Clinical Benefits of The Cypher(R) Sirolimus-Eluting Coronary Stent - Aug 21, 2005 Data from the randomized, head to head Sirolimus-eluting and Paclitaxel-eluting Stents for Coronary Revascularization (SIRTAX) study and the ... Medical News Today - Medical News Today (press release) MacuSight reports positive phase 1 results for sirolimus - Feb 25, 2008 UNION CITY, Calif. — MacuSight reported positive preliminary data from a phase 1 trial of sirolimus, an immunosuppressant and antiangiogenic drug being ... OSN SuperSite SESAMI: Sirolimus Stent vs Bare Stent in Acute Myocardial Infarction - Jun 9, 2006 ...". . . the SESAMI results are encouraging and provide further proof of the safety of sirolimus-eluting stents in STEMI patients. Such findings are likely to ... Medscape CYPHER® Sirolimus-Eluting Coronary Stent Demonstrates Sustained … - Sep 10, 2007 Clinical investigators at the European Society of Cardiology Congress 2007 (ESC Congress 2007) reported that the CYPHER® Sirolimus-eluting Coronary Stent ... Medical News Today - Medical News Today (press release) Tirofiban Plus Sirolimus-Eluting Stent vs Abciximab Plus Bare-Metal... - Oct 5, 2005 In Reply: We agree with some of the comments raised by Dr Osman and colleagues, as we noted in the discussion of the limitations of our study. ... Journal of American Medical Association - Journal of American Medical Association... Treatment of Refractory Chronic Urticaria With Sirolimus - Jun 24, 2008 A 52-year-old woman with prediabetes reported 5 years of chronic urticaria (CU) with daily flare-ups that had abruptly worsened 1 month previously, ... Archives of Dermatology … Better Outcomes With The CYPHER® Sirolimus-Eluting Coronary Stent ... - Mar 12, 2006 The SISR Trial (A Randomized Trial Comparing Sirolimus-Eluting Stent with ... Sirolimus, the active drug released for the stent, is marketed by Wyeth ... Angioplasty.Org … Initial Results From Phase 1 Study of Sirolimus in Diabetic... - Oct 1, 2007 This finding raises the possibility that sirolimus may be fundamentally changing the ... Sirolimus, originally known as rapamycin, is a highly-potent, ... Free with registration - PR Newswire - AccessMyLibrary.com Study confirms drug-coated stents better for treating heart attacks. - May 3, 2005 The Cypher device is coated with a drug known as sirolimus. The Taxus device is coated with paclitaxel. Both devices are inserted into arteries using a ... Free with registration - Milwaukee Journal Sentinel - AccessMyLibrary.com Drug-releasing heart stents safe for wide use: study - Jan 30, 2008 The study also found no significant difference in the effectiveness of the two stents in releasing the medications, sirolimus and paclitaxel. ... Sydney Morning Herald Data Suggest the Cypher(R) Sirolimus-Eluting Coronary Stent Provides ... - Sep 6, 2006 BARCELONA, Spain, Sept. 6 /PRNewswire/ -- At four years, the CYPHER(R) Sirolimus-eluting Coronary Stent continues to provide long-term clinical benefits ... Free with registration - PR Newswire - AccessMyLibrary.com … MINISTRY ASSIGNS PRICE PREMIUM TO CYPHER SIROLIMUS- … - Dec 2, 2005 Cordis Corporation today announced that Italy's Ministry of Health has established a higher price premium for the CYPHER(R) Sirolimus-eluting Coronary Stent ... Free with registration - AsiaPulse News - AccessMyLibrary.com CYPHER® Sirolimus-Eluting Coronary Stent Demonstrates Sustained … - Sep 6, 2007 Vienna, Austria .–Clinical investigators at the European Society of Cardiology Congress 2007 (ESC Congress 2007) reported today that the CYPHER® ... webwire.com CYPHER SELECT® Plus Sirolimus-eluting Coronary Stent Receives CE … - Aug 27, 2008 Cordis Corporation today announced that it has received CE mark approval to market the CYPHER SELECT® Plus Sirolimus-eluting Coronary Stent for the ... webwire.com … Evaluation of New Therapies -- Paclitaxel- vs Sirolimus-Eluting... - Apr 12, 2006 Comparative late clinical outcomes of paclitaxel and sirolimus-eluting ... Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. ... Medscape Transplant drug sirolimus shrinks tumors, improves lung function - Jan 9, 2008 CINCINNATI - The drug sirolimus, normally used to help transplant patients fight organ rejection, may eventually be used as a less invasive treatment for a ... eurekalert.org Sirolimus-Eluting Stents vs Brachytherapy for Restenosis - Oct 18, 2006 To the Editor: Dr Holmes and colleagues 1 reported the results of the Sirolimus-Eluting Stent vs Brachytherapy in Patients With Bare Metal In-Stent ... Journal of American Medical Association - Journal of American Medical Association... Fewer Heart Attacks Reported with Cypher (Sirolimus-Eluting) Stent - Sep 14, 2007 By Peggy Peck, Executive Editor, MedPage Today. BERN, Switzerland, Sept. 14 -- The two major drug-eluting stents and bare-metal devices emerged in a ... MedPage Today Biochemical monitoring of mTOR inhibitor–based immunosuppression … - Mar 20, 2005 We found that sirolimus treatment was associated with a pronounced inhibition of ... In sirolimus-treated patients, phosphorylation of the p70S6 kinase was ... Nature.com CYPHER(R) Sirolimus-Eluting Coronary Stent Outperforms Taxus Stent in... - Feb 2, 2006 MIAMI, Feb. 2 /PRNewswire-FirstCall/ -- Results from a prospective, randomized clinical trial of small coronary vessels suggest that the CYPHER(R) Stent ... Free with registration - PR Newswire - AccessMyLibrary.com … Collaboration and License Agreement for Sirolimus in Ocular... - Jun 2, 2008 MacuSight is presently initiating a Phase 2 clinical trial of sirolimus in ... MacuSight retains development and commercialization rights to sirolimus in ... Genetic Engineering News - Genetic Engineering News (press release) … Excellent Outcomes for CYPHER(R) Sirolimus-Eluting Coronary Stent... - Oct 21, 2007 WASHINGTON -- Implantation of the CYPHER([R]) Sirolimus-eluting Coronary Stent to treat completely blocked coronary arteries led to substantial reductions ... $4.95 - Business Wire - ECNext Study Results Indicate the CYPHER Sirolimus-Eluting Coronary Stent … - Feb 3, 2006 MIAMI, January 31, 2006 /PRNewswire/ -- The CYPHER(R) Sirolimus-Eluting Coronary Stent may reduce re-blockage (restenosis) and the occurrence of major ... 生物谷 RAVEL: Sirolimus-Eluting Stent vs Bare-Metal Stent in Simple Lesions - Dec 26, 2006 ..."These long-term results provide us with food for thought, emphasizing that we should carefully reassess which patients and which lesions should be treated ... Medscape Promising Treatment For High Risk Kidney Recipients In First Year... - Nov 24, 2006 Data from a 12-month, open-label study indicate that sirolimus-based therapy in ... "Our team of investigators was able to determine that sirolimus, ... Medical News Today - Medical News Today (press release) Sirolimus Increases Graft Survival in Orthotopic Liver Transplant … - Jun 6, 2008 By Thomas S. May. TORONTO -- June 6, 2008 -- Although sirolimus has no impact on patient survival, it significantly increases graft survival in recipients ... DG News Kidney Transplant Patients Who Took Rapamune(R) Achieved Superior … - May 23, 2005 ..."This study confirms that 2-4 months post-transplantation, sirolimus can be used ... RAPAMUNE(R) (sirolimus) is indicated for the prophylaxis of organ ... RedOrbit FDA accepts MacuSight drug application - Aug 8, 2006 Sirolimus, originally named rapamycin, is an immunosuppressant that can affect angiogenesis, the growth of new blood vessels. Wet AMD is caused by the rapid ... Bizjournals.com Sirolimus-Releasing Stents More Effective Than VBT For Treating … - Mar 17, 2006 CHICAGO, IL -- MARCH 17, 2006 -- David R. Holmes, Jr., MD, of Mayo Clinic, Rochester, Minn., and colleagues with the SISR trial compared the use of vascular ... DG News … clinical trial results show the Cypher sirolimus-eluting coronary... - Oct 23, 2006 Results from a multi-centre, prospective, randomised clinical trial indicate that the Cypher Stent performed better than the Taxus Stent in procedures ... Pay-Per-View - Company Reports - Factiva, from Dow Jones Economic evaluation of sirolimus-eluting stents - Jun 1, 2008 Fiona M. Shrive, Braden J. Manns, P. Diane Galbraith, Merril L. Knudtson and William A. Ghali for The APPROACH Investigators ... CMAJ Mycophenolate Mofetil/Sirolimus After Calcineurin Inhibitor Withdrawal... - Jun 6, 2008 By Thomas S. May. TORONTO -- June 6, 2008 -- Results of the Spare the Nephron study show that a maintenance regimen based on the combined use of ... DG News Sirolimus-Releasing Stents More Effective than VBT for Treating … - Mar 9, 2006 Newswise — David R. Holmes, Jr., MD, of Mayo Clinic, Rochester, Minn., and colleagues with the SISR trial compared the use of vascular brachytherapy (VBT ... newswise.com Sirolimus Reduces Angiomyolipoma Tumors - Jan 10, 2008 January 10, 2008 — Year-long treatment with the immunosuppressive drug sirolimus led to shrinkage of angiomyolipoma tumors, with volume reduced by nearly ... Medscape CYPHER(R) Sirolimus-eluting Coronary Stent Demonstrates Sustained … - Mar 29, 2007 Clinical investigators at the American College of Cardiology's 56th Annual Scientific Session (ACC.07) reported today that the clinical benefit of the ... Medical News Today - Medical News Today (press release) … instructions for use for the Cypher Sirolimus-eluting coronary... - Jan 23, 2006 Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth. Pay-Per-View - Company Reports - Factiva, from Dow Jones CYPHER® Sirolimus-Eluting Coronary Stent to Be Featured in Late- … - Feb 28, 2005 ...(I-Newswire) - Clinical data regarding the use of the CYPHER® Sirolimus-eluting Coronary Stent in difficult-to-treat coronary lesions will be presented at ... i-newswire.com … for Pivotal Trial of the NEVO(TM) Sirolimus-eluting Coronary Stent... - Oct 27, 2008 NEVO(TM) contains the same drug, sirolimus, as in the CYPHER(R) Sirolimus-eluting ... The data supporting the safety and efficacy of sirolimus in coronary ... Genetic Engineering News - Genetic Engineering News (press release) … of Pneumonitis in Kidney Transplantation Recipients Receiving... - Apr 4, 2006 One such drug is sirolimus. There have been previous reports of a lung condition called pneumonitis in kidney transplant recipients who took sirolimus. ... Annals of Internal Medicine Emerging efficacy and safety data and clinical considerations.(Drug- … - Oct 1, 2006 Since their introduction to the US market in 2004, the sirolimus- and ... The trials included were 4 with the sirolimus-eluting stent (RAVEL, SIRIUS, ... Free with registration - Formulary - AccessMyLibrary.com … Excellent Patient, Graft Survival With Sirolimus Plus Tacrolimus... - Aug 14, 2008 The randomised, open-label, comparative study compared the efficacy of 2 sirolimus regimens versus mycophenolate mofetil (MMF) plus tacrolimus. ... DG News Calcineurin-Inhibitor Withdrawal May Improve Renal Allograft Outcomes - Jun 19, 2008 Calcineurin-inhibitor withdrawal and continuation of sirolimus plus steroids ... "The model suggests that treatment with sirolimus plus steroids is more ... MedPage Today … Patient Outcomes with CYPHER(R) Sirolimus-Eluting Coronary Stent … - Jun 4, 2007 Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the markets. ... Free with registration - M2 Presswire - AccessMyLibrary.com Anti-rejection Drug May Increase Risk Of Diabetes After Kidney … - May 26, 2008 ..."We demonstrated a robust association between sirolimus and diabetes after ... Treatment with sirolimus was analyzed as a possible contributor to the risk ... sciencedaily.com Stents that release medication appear more effective than traditional... - May 4, 2005 Sirolimus, a substance that is thought to help prevent reclosure of coronary ... Patients received either tirofiban regimen plus sirolimus-eluting stenting ... Medical News Today - Medical News Today (press release) Coronary stents that release the drugs sirolimus or paclitaxel... - Feb 24, 2006 Use of coronary stents that release the drugs sirolimus or paclitaxel produced similar results in patients with new coronary artery lesions, according to a ... News-Medical.net FDA Approvals: Retisert, WinRho SDF, IMx Sirolimus Assay - Apr 28, 2005 April 28, 2005 — The US Food and Drug Administration (FDA) has approved fluocinolone acetonide 0.59-mg intravitreal implant for the treatment of chronic ... Medscape Sirolimus: acute rejection in renal transplant patients.(Safety and... - Sep 22, 2006 Canada -- Increased risk of rejection in de novo renal transplant patients receiving sirolimus (Rapamune[R]), mycophenolate mofetil, and corticosteroid, ... Free with registration - WHO Drug Information - AccessMyLibrary.com … For Use For The CYPHER(R) Sirolimus-Eluting Coronary Stent - Jan 30, 2006 The trials and registries include SIRIUS (SIRolImUS-coated BX VELOCITY(R) ... Sirolimus, the active drug released for the stent, is marketed by Wyeth ... Medical News Today - Medical News Today (press release) CYPHER® Sirolimus-Eluting Coronary Stent Had Similar Results To … - May 29, 2007 A three-year follow-up subset analysis presented today as a late-breaking clinical trial at EuroPCR 2007 showed that the CYPHER® Sirolimus-eluting Coronary ... Medical News Today - Medical News Today (press release) Sirolimus as good as current CIN immunosuppression - Mar 1, 2006 Rochester, MN - Use of sirolimus in immunosuppressive protocols in kidney transplantation provides excellent patient and allograft survival with low rates ... Medscape Sirolimus maintenance regimen improves graft survival in kidney … - Jul 1, 2005 Kidney transplant recipients on an immunosuppressive regimen of sirolimus plus cyclosporine who had their cyclosporine withdrawn at an early stage had ... Free with registration - Formulary - AccessMyLibrary.com Study Suggests CYPHER(R) Sirolimus-Eluting Coronary Stent More Cost- … - Jul 27, 2006 MIAMI, July 27 /PRNewswire/ -- The CYPHER(R) Sirolimus-eluting Coronary Stent is more cost-effective than the Taxus Stent for treating patients at high risk ... Free with registration - PR Newswire - AccessMyLibrary.com Long Term Sirolimus Data Brings Hope for Kidney Transplant Patients. - Jan 31, 2005 VIENNA, Austria, Jan. 31 /PRNewswire/ -- New long-term data published today in Transplant International from the Rapamune Maintenance Regimen study (RMR) ... $4.95 - PR Newswire - ECNext Anti-Rejection Drugs After Transplant, Increase Diabetes Risk: Study - May 30, 2008 Treatment with Sirolimus – a relatively new immunosuppressant drug used to prevent ... Though no association between Sirolimus usage and development of ... TheMedGuru Coronary Artery Stents Prove Effective for Patients with Heart Attack - May 8, 2005 Chicago, Ill. - infoZine - Sirolimus, a substance that is thought to help ... Patients received either tirofiban regimen plus sirolimus-eluting stenting (n ... Kansas City infoZine … From Standard Cyclosporine to Sirolimus Regimen Is Effective, Safe... - Aug 14, 2008 By Rachel Parratt. SYDNEY, Australia -- August 14, 2008 -- Preliminary data from the Supporting Medication Adherence in Renal Transplantation (SMART) study ... DG News Cardiology; Sirolimus-eluting coronary stent marks 1 millionth... - Mar 20, 2005 2005 MAR 20 - (NewsRx.com) -- Cordis Corporation announced that its Cypher Sirolimus-eluting coronary stent has been used for more than 1 million cardiac ... Pay-Per-View - Medical Devices & Surgical Technology... - Factiva, from Dow Jones … of Positive Data for the CYPHER(R) Sirolimus-eluting Coronary Stent - Oct 30, 2008 The CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent, a third generation ... Sirolimus, the active drug released for the stent, is marketed by Wyeth ... Genetic Engineering News - Genetic Engineering News (press release) … Collaboration and License Agreement for Sirolimus in Ocular Diseas - Jun 2, 2008 MacuSight is presently initiating a Phase 2 clinical trial of sirolimus in ... MacuSight retains development and commercialization rights to sirolimus in ... Pay-Per-View - PR Newswire - HighBeam Research Sirolimus Reduces the Risk of Cancer in Kidney Transplant Patients - Feb 9, 2006 BERLIN, GERMANY -- February 9, 2006 -- A new study published in this month's issue of the Journal of the American Society of Nephrology shows that the risk ... DG News CYPHER® Sirolimus-Eluting Coronary Stent Receives FDA Approval for … - Apr 20, 2005 MIAMI, April 20 -- Cordis Corporation, a Johnson & Johnson company, today announced that the US Food and Drug Administration (FDA) has approved a condition ... Angioplasty.Org Study shows anticoagulant drugs have similar outcomes after angioplast... - Mar 31, 2008 The researchers also found that patients who received coated stents that released the drug sirolimus had a lower risk of major adverse cardiac events within ... thecheers.org Safety and Efficacy of the Cypher(R) Sirolimus-Eluting Coronary Stent... - Jun 8, 2005 Data from three studies presented at the 2005 EuroPCR Congress highlighted the continued success of the CYPHER(R) Sirolimus-eluting Coronary Stent in ... Medical News Today - Medical News Today (press release) Analyzing The Side Effects Of Sirolimus Stents - Jul 20, 2005 Based on findings of a recent study researchers from Sweden say they have found that implantation of a sirolimus-eluting stent is associated with coronary ... MedIndia Sirolimus and Tacrolimus Without Methotrexate Appear Promising for … - Dec 12, 2005 By Bruce Sylvester. ATLANTA, GA -- December 12, 2005 -- Immunosuppressants sirolimus (Rapamycin) and tacrolimus (Prograf) used without methotrexate appear ... DG News Brand Names/Synonyms: Sirolimus is also known by the following brand names and/or synonymsAntibiotic Ay 22989; Rapamune; Rapamycin; Rapamycin / Sirolimus; Rapamycin, ≪ 98% by Tlc; Sirolimus; Sirolimus [Usan:Ban:Inn] Drug Category: Sirolimus is categorized under the following by the FDA: Immunosuppressive Agents; Antifungals; Antibiotics; Anti-bacterial Agents; Unclassified Therapeutic Agents (92:00.00); ATC:L04AA10 Dosage Forms: SOLUTION Absorption: Not Available Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: Not Available |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |